Theravance Biopharma
TBPH
89 hedge funds and large institutions have $369M invested in Theravance Biopharma in 2015 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 32 increasing their positions, 29 reducing their positions, and 15 closing their positions.
236% more call options, than puts
Call options by funds: $94K | Put options by funds: $28K
15% more capital invested
Capital invested by funds: $320M → $369M (+$48.6M)
10% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 29
4% less funds holding
Funds holding: 93 → 89 (-4)
20% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
+$12.2M |
| 2 |
AC
Armistice Capital
New York
|
+$9.39M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
+$5.6M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$5.5M |
| 5 |
UBS AM
Chicago,
Illinois
|
+$4.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$9.94M |
| 2 |
FAM
Foundation Asset Management
White Plains,
New York
|
-$6.42M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.74M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.01M |
| 5 |
D.E. Shaw & Co
New York
|
-$3.6M |
TBPH Hedge Fund Activity: Q1 2015 in Review
89 of the 3,752 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q1 2015, worth a combined $369M — up 15% from $320M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of TBPH and 12 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 32 added.
The largest buyer was Norges Bank, adding an estimated $12.2M. The largest seller was Capital World Investors, cutting an estimated $9.94M.
- 89 institutional investors held Theravance Biopharma (TBPH) as of Q1 2015, down from 93 in Q4 2014.
- Funds reported $369M of Theravance Biopharma stock for Q1 2015, up 15% quarter-over-quarter.
- 12 funds opened new Theravance Biopharma positions in Q1 2015 and 15 closed out, a net change of -3 holders.
- The largest Theravance Biopharma buyer in Q1 2015 was Norges Bank, an estimated $12.2M added.
- The largest Theravance Biopharma seller in Q1 2015 was Capital World Investors, an estimated $9.94M sold.
Based on aggregated 13F filings for Q1 2015.